Details

Autor(en) / Beteiligte

• Sandler, Netanya G.
• Zhang, Xinyan
• Bosch, Ronald J.
• Funderburg, Nicholas T.
• Choi, Andrew I.
• Robinson, Janet K.
• Fine, Derek M.
• Coombs, Robert W.
• Jacobson, Jeffrey M.
• Landay, Alan L.
• Douek, Daniel C.
• Tressler, Randall
• Read, Sarah W.
• Wilson, Cara C.
• Deeks, Steven G.
• Lederman, Michael M.
• Gandhi, Rajesh T.

Titel

Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection

Ist Teil von

• The Journal of infectious diseases, 2014-11, Vol.210 (10), p.1549-1554

Ort / Verlag

Oxford: Oxford University Press

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.